Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
1. A study highlighted inaccuracies in clinical fluid status assessments. 2. 48% of COVID-19 patients misclassified as hypervolemic despite being hypovolemic. 3. Daxor's BVA technology was featured as a reliable diagnostic tool. 4. New FDA clearance for a faster blood volume analyzer enhances diagnostics. 5. Daxor aims for revenue growth in critical care sectors using new data.